# Electromed, Inc.: overview ELMD · NYSE · CIK 1488917 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/elmd.md) · [Financials](/companies/elmd/financials.md) · [Filings](/companies/elmd/filings.md) · [Insiders](/companies/elmd/insiders.md) Latest reported revenue: [$19.4m](/filings/0001437749-26-028914.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Aug 25, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-028914). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [14.7](/filings/0001437749-25-034445.md) | [16.3](/filings/0001437749-26-003635.md) | [15.7](/filings/0001437749-26-016429.md) | [17.4 d](/filings/0001437749-26-028914.md) | [16.9](/filings/0001437749-25-034445.md) | [18.9](/filings/0001437749-26-003635.md) | [18.6](/filings/0001437749-26-016429.md) | [19.4 d](/filings/0001437749-26-028914.md) | | Gross margin | % | [78.3%](/filings/0001437749-25-034445.md) | [77.7%](/filings/0001437749-26-003635.md) | [78.0%](/filings/0001437749-26-016429.md) | [78.3% d](/filings/0001437749-26-028914.md) | [78.1%](/filings/0001437749-25-034445.md) | [78.4%](/filings/0001437749-26-003635.md) | [78.8%](/filings/0001437749-26-016429.md) | [78.7% d](/filings/0001437749-26-028914.md) | | Operating margin | % | [13.2%](/filings/0001437749-25-034445.md) | [15.6%](/filings/0001437749-26-003635.md) | [13.6%](/filings/0001437749-26-016429.md) | [17.5% d](/filings/0001437749-26-028914.md) | [15.8%](/filings/0001437749-25-034445.md) | [19.2%](/filings/0001437749-26-003635.md) | [20.3%](/filings/0001437749-26-016429.md) | [19.7% d](/filings/0001437749-26-028914.md) | | Net margin | % | [10.0%](/filings/0001437749-26-016429.md) | [12.1%](/filings/0001437749-26-016429.md) | [12.1%](/filings/0001437749-26-016429.md) | [12.7% d](/filings/0001437749-26-028914.md) | [12.6%](/filings/0001437749-26-016429.md) | [14.6%](/filings/0001437749-26-016429.md) | [16.2%](/filings/0001437749-26-016429.md) | [17.5% d](/filings/0001437749-26-028914.md) | | Diluted EPS | $ per share | [0.16](/filings/0001437749-25-034445.md) | [0.22](/filings/0001437749-26-003635.md) | [0.21](/filings/0001437749-26-016429.md) | not reported | [0.25](/filings/0001437749-25-034445.md) | [0.32](/filings/0001437749-26-003635.md) | [0.35](/filings/0001437749-26-016429.md) | not reported | | Free cash flow | $m | [2.3](/filings/0001437749-25-034445.md) | [2.9 d](/filings/0001437749-26-003635.md) | [1.9 d](/filings/0001437749-26-016429.md) | [3.7 d](/filings/0001437749-26-028914.md) | [(0.1)](/filings/0001437749-25-034445.md) | [2.4 d](/filings/0001437749-26-003635.md) | [3.3 d](/filings/0001437749-26-016429.md) | [2.8 d](/filings/0001437749-26-028914.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [41.7](/filings/0000897101-23-000380.md) | [48.1](/filings/0000897101-24-000422.md) | [54.7](/filings/0001437749-25-027761.md) | [64.0](/filings/0001437749-26-028914.md) | [73.8](/filings/0001437749-26-028914.md) | | Gross margin | % | [75.5%](/filings/0000897101-23-000380.md) | [76.0%](/filings/0000897101-24-000422.md) | [76.3%](/filings/0001437749-25-027761.md) | [78.1%](/filings/0001437749-26-028914.md) | [78.5%](/filings/0001437749-26-028914.md) | | Operating margin | % | [7.1%](/filings/0000897101-23-000380.md) | [8.3%](/filings/0000897101-24-000422.md) | [12.0%](/filings/0001437749-25-027761.md) | [15.1%](/filings/0001437749-26-028914.md) | [18.8%](/filings/0001437749-26-028914.md) | | Net margin | % | [5.5%](/filings/0000897101-23-000380.md) | [6.6%](/filings/0000897101-24-000422.md) | [9.4%](/filings/0001437749-25-027761.md) | [11.8%](/filings/0001437749-26-028914.md) | [15.3%](/filings/0001437749-26-028914.md) | | Diluted EPS | $ per share | [0.26](/filings/0000897101-23-000380.md) | [0.36](/filings/0000897101-24-000422.md) | [0.58](/filings/0001437749-25-027761.md) | [0.85](/filings/0001437749-26-028914.md) | [1.30](/filings/0001437749-26-028914.md) | | Free cash flow | $m | [(2.1)](/filings/0000897101-23-000380.md) | [(0.3)](/filings/0000897101-24-000422.md) | [8.8](/filings/0001437749-25-027761.md) | [11.1](/filings/0001437749-26-028914.md) | [8.4](/filings/0001437749-26-028914.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/elmd/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [J.E. Simmons & Co., P.C.](/funds/2111381.md) | 2026-06-30 | $20.5m | 483,822 | | Reduced −9,000 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $19.7m | 465,619 | | Added +6,774 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $12.0m | 283,232 | | Reduced −51,796 | | [PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.](/funds/1238990.md) | 2026-06-30 | $9.2m | 218,520 | | Reduced −6,000 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $9.2m | 217,115 | | Added +15,222 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $7.6m | 180,447 | | Added +2,177 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $7.1m | 167,492 | | Reduced −36,108 | | [GAMCO INVESTORS, INC. ET AL](/funds/807249.md) | 2026-06-30 | $6.0m | 142,000 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $4.8m | 112,616 | | Added +6,253 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $4.2m | 99,704 | | Reduced −24,300 | ## Recent filings [All 578 filings](/companies/elmd/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-29 | 16:17 ET | [DEF 14A](/filings/0001437749-26-031465.md) | Proxy statement, period 2026-11-13 | 0001437749-26-031465 | | 2026-08-25 | 16:11 ET | [8-K](/filings/0001437749-26-028915.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-028915 | | 2026-08-25 | 16:11 ET | [10-K](/filings/0001437749-26-028914.md) | Annual report, period 2026-06-30 | 0001437749-26-028914 | | 2026-05-12 | 16:10 ET | [10-Q](/filings/0001437749-26-016429.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016429 | | 2026-05-12 | 16:06 ET | [8-K](/filings/0001437749-26-016422.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-016422 | | 2026-02-10 | 16:11 ET | [10-Q](/filings/0001437749-26-003635.md) | Quarterly report, period 2025-12-31 | 0001437749-26-003635 | | 2026-02-10 | 16:11 ET | [8-K](/filings/0001437749-26-003636.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-003636 | | 2025-12-18 | 16:46 ET | [8-K](/filings/0001437749-25-038291.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001437749-25-038291 | | 2025-11-18 | 16:17 ET | [8-K](/filings/0001437749-25-035598.md) | 5.07 Shareholder vote results | 0001437749-25-035598 | | 2025-11-12 | 16:11 ET | [10-Q](/filings/0001437749-25-034445.md) | Quarterly report, period 2025-09-30 | 0001437749-25-034445 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001437749-26-028914.md), filed Aug 25, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1e9b154f-7908-47fe-b4dd-215aa260515b) ## About the filer - CIK: 1488917 - Tickers: ELMD - Exchange: NYSE - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: MN - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.